MedTrace Logo

Changing the coUrse of cRohn's Disease With an Early Use of Adalimumab

NCT03306446 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 203

Last updated 2023-05-31

No results posted yet for this study

Summary

This is a prospective, longitudinal, multicenter study conducted in a cohort of patients with early CD. This study will not change the patient/physician relationship.

Conditions

Interventions

DRUG

Start adalimumab in monotherapy

Discontinuation of Adalimumab in patients who achieved deep remission

Sponsors & Collaborators

  • Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives

    lead OTHER

Principal Investigators

  • Yoram Bouhnik, MD · Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives

  • Laurent Peyrin-Biroulet, MD, PhD · Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-17
Primary Completion
2021-03-31
Completion
2025-03-31

Countries

  • Belgium
  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03306446 on ClinicalTrials.gov